ClinicalTrials.gg
CompletedNCT04603443SmART-TBIUpdated Oct 28, 2026Results posted

SmART-TBI: Supplementation With Amino Acid Rehabilitative Therapy in TBI

An interventional study of Branched Chain Amino Acids and Branched Chain Amino Acids in Traumatic Brain Injury, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Updated Oct 28, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Brain Injuries, Traumatic · VA Office of Research and Development.

Enrollment
6th of 46
175 · median 61
Started
2021
with 2 others
No phase
37 of 55
4 open now
Registered
43rd of 55
by date

Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, this one is the 6th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2021, is one of 37 with no phase, and was the 43rd registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

8 of the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

The most persistent and disabling postconcussive symptoms following mild traumatic brain injury (mTBI) are sleep disturbances and cognitive dysfunction, with few tractable interventions currently available. Here, a novel therapy will be tested consisting of dietary supplementation with branched chain amino acids (BCAA), based on the study team's previous preclinical work showing restoration of glutamate neurotransmitter balance in sleep and memory circuits. Supplementation with Amino acid Rehabilitative Therapy in TBI (SmART-TBI) is a randomized, placebo-controlled, double-blinded, exploratory clinical trial of BCAA intended to establish the feasibility, acceptability, and limited efficacy of long-term BCAA to improve sleep and cognition in Veterans with mTBI. These results will inform the optimal study design of a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may benefit the most.

Read the detailed description

Mild traumatic brain injury (mTBI) has impacted over 60% of all OEF/OIF Veterans over the past decade, and over 20% of these Veterans carry a diagnosis of postconcussion syndrome. Arguably the most disabling postconcussion symptoms are sleep-wake and cognitive disturbances. Sleep, cognitive function, and related symptoms often remain impaired >10-15 years following mTBI. Not only are these symptoms themselves exceedingly difficult to live with, but poor sleep and cognition also interfere with ongoing rehabilitation interventions, and prevent reintegration into civilian life and return to gainful employment. Most existing therapies for sleep-wake and cognitive dysfunction following mTBI are merely symptomatic, and they also suffer from low efficacy and/or patient acceptability. Thus, there is an urgent need to identify mechanism-based interventions for sleep and cognitive problems following mTBI, in order to facilitate optimal rehabilitation and functional outcomes.

The study team's long-term goal is to implement a brain-bioactive pharmacological intervention to address sleep and cognitive disturbance in individuals with mTBI. The overall objective of this application, which represents the first step towards this goal, is to test the feasibility and limited efficacy of a highly promising therapy consisting of a dietary supplement, branched chain amino acids (BCAA; i.e., leucine, isoleucine, and valine), to treat sleep disturbances in individuals with mTBI. There is compelling scientific precedent and safety data to support the testing of BCAA therapy in Veterans with mTBI. Preliminary preclinical data has shown that the mechanism of action for BCAA, acting as a precursor to the excitatory neurotransmitter glutamate, restores the balance of excitation to inhibition within the dysfunctional brain circuits for both sleep and cognition in mTBI. With these data, the study team has also meticulously mapped the optimal dosing, duration, and route of administration in mice. Further, the study team now has pilot data from a double-blinded, placebo-controlled study showing that 3 weeks of dietary BCAA supplementation, but not placebo, significantly improved self-reported sleep in Veterans. Other research groups have used dietary BCAA supplementation in humans across multiple conditions at doses up to 60 grams/day and durations up to 12 months with few to no side effects.

The central hypothesis is that BCAA dietary supplementation will improve sleep quality in Veterans with mTBI. As a first step towards testing this hypothesis, herein is proposed a long-term feasibility, acceptability, and limited efficacy study of BCAA's effects on sleep that will be randomized, placebo-controlled, and double-blinded. Veterans with mTBI will be randomly assigned to receive BCAA at 20, 40 or 60 grams/day per oral (PO) or a placebo (n=50 per group) for 12 weeks. Feasibility, acceptability, and limited efficacy outcomes based on sleep (e.g., self-report, continuous actigraphy, and overnight polysomnography) will be assessed.

Results will inform the optimal study methodology and design for a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may be differentially affected by BCAA. This work will aos be used to generate hypotheses on the effect of BCAA on cognition and overall quality of life measures to inform future research.

03

Conditions studied

  • Traumatic Brain Injury

Keywords

  • TBI
  • sleep
  • cognition
  • bcaa
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be Veterans (male and female; any race; 18-65 years of age)
  • Be English speaking
  • Be accessible via phone
  • Be non-decisionally impaired
  • Attest to there being no chance of being or becoming pregnant during the study (if female)
  • Attest to no history of maple syrup urine disease or known family history of maple urine syrup disease
  • Have either a history of self-reported sleep disturbances, either as determined via the Insomnia Severity Index, Functional Outcomes of Sleep Questionnaire or Epworth Sleepiness Scale, clinical assessment, and/or a history of self-reported cognitive disturbance (e.g., poor memory, concentration, attention)
  • Not have an allergy to sucralose
  • Not be a shift worker (e.g. have worked night or rotating shifts more than twice in the past month)
  • Not have a diagnosis of amyotrophic lateral sclerosis
  • Not be currently supplementing their diet with branched chain amino acids
  • Not be starting another sleep intervention (e.g., positive airway pressure therapy for sleep apnea, sedative-hypnotic medication, or cognitive behavioral therapy for insomnia) during the study

    • if already engaged in another sleep intervention, this must be stable and not undergo further changes during the study
  • Meet diagnostic criteria for TBI using a validated clinical interview

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or female trying to conceive
  • Under 18 years old
  • Known history of maple syrup urine disease
  • Dementia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    BCAA 20g/daily

    Branched Chain Amino Acids, 10g BID x 12 weeks

    Dietary Supplement: Branched Chain Amino Acids

  • Experimental
    BCAA 40g/daily

    Branched Chain Amino Acids, 20g BID x 12 weeks

    Dietary Supplement: Branched Chain Amino Acids

  • Experimental
    BCAA 60g/daily

    Branched Chain Amino Acids, 30g BID x 12 weeks

    Dietary Supplement: Branched Chain Amino Acids

  • Placebo comparator
    Placebo 20g/daily

    Protein without BCAA, 10g BID x 12 weeks

    Dietary Supplement: Protein Control

Interventions

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction With Overall Study Process

    Likert scale (1-5, higher= more satisfied) assessing satisfaction with consent process, staff, medication dispensing and regimen, devices/equipment, sleep study, questionnaires, cognitive testing, and overall experience of the study.

    Time frame: 12 weeks

  2. Monitoring of Side Effects Scale (MOSES)

    Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.

    Time frame: 4 weeks

  3. Change in Monitoring of Side Effects Scale (MOSES)

    Change in average score between week 8 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.

    Time frame: 8 weeks

  4. Change in Monitoring of Side Effects Scale (MOSES)

    Change in average score between week 12 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.

    Time frame: 12 weeks

  5. Reasons for Non-adherence

    Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.

    Time frame: 4 weeks

  6. Reasons for Non-adherence

    Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.

    Time frame: 8 weeks

  7. Reasons for Non-adherence

    Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.

    Time frame: 12 weeks

  8. Recruitment Source

    Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)

    Time frame: Year 1

  9. Recruitment Source

    Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)

    Time frame: Year 2

  10. Recruitment Source

    Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)

    Time frame: Year 3

  11. Recruitment Source

    Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)

    Time frame: Year 4

  12. Recruitment

    Number of subjects randomized of those eligible as descriptive percent

    Time frame: Year 1

  13. Recruitment

    Number of subjects randomized of those eligible as descriptive percent

    Time frame: Year 2

  14. Recruitment

    Number of subjects randomized of those eligible as descriptive percent

    Time frame: Year 3

  15. Recruitment

    Number of subjects randomized of those eligible as descriptive percent

    Time frame: Year 4

  16. Study Drug Adherence by Serum

    Proportion of study drug consumed assessed by serum of BCAA.

    Time frame: 12 weeks

  17. Study Drug Adherence by Sleep Diary

    Proportion of study drug consumed assessed by sleep diary.

    Time frame: 12 weeks

  18. Study Drug Adherence by Drug Accounting

    Proportion of study drug consumed within each timepoint assessed by drug accounting.

    Time frame: 12 weeks

  19. Actiwatch Adherence

    Proportion of days with actiwatch worn

    Time frame: 12 weeks

  20. Screen Failures

    Number of enrolled participants who were later found ineligible

    Time frame: From enrollment to randomization (~4 weeks)

  21. Incidence of Non-Participation

    Reason for not participating after initial contact and before consent as descriptive percent

    Time frame: From first contact to declining (~1 week)

  22. Retention by Arm

    Number of participants retained by study arm

    Time frame: From randomization to study completion (~12 weeks)

Secondary outcomes

  1. Change in Insomnia Severity Index (ISI) From Baseline

    Change in Insomnia Severity Index (ISI) range: 0-28, higher means worse sleep

    Time frame: 12 weeks

07

Results

Posted Oct 1, 2026
Limitations and caveats
All results reported here are raw, unadjusted values. Due to attrition by 12 weeks, longer term effects of intervention should be interpreted with caution.

Participant flow

Participant flow — Overall Study
MilestoneBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Started40374537
Completed24141824
Not completed16232713
Withdrew: Lost to follow-up7984
Withdrew: Withdrawal by subject914199

Outcome measures

PrimaryPatient Satisfaction With Overall Study Process

Likert scale (1-5, higher= more satisfied) assessing satisfaction with consent process, staff, medication dispensing and regimen, devices/equipment, sleep study, questionnaires, cognitive testing, and overall experience of the study.

Time frame:
12 weeks
Reported as:
Mean · Units on a Scale
Patient Satisfaction With Overall Study Process
Units on a ScaleBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Patient Satisfaction With Overall Study Process4.2 ± 1.04.2 ± 1.04.5 ± 0.74.5 ± 0.8
Statistical analysis
  • BCAA 20g/Daily vs BCAA 40g/Daily vs BCAA 60g/Daily vs Placebo 20g/Daily · ANOVA · p = 0.163 (To determine if there are significant differences in reported satisfaction with the study between the groups.)
PrimaryMonitoring of Side Effects Scale (MOSES)

Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.

Time frame:
4 weeks
Reported as:
Mean · Units on a Scale
Monitoring of Side Effects Scale (MOSES)
Units on a ScaleBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Monitoring of Side Effects Scale (MOSES)7.2 ± 10.99.0 ± 18.78.2 ± 8.97.3 ± 13.4
Statistical analysis
  • BCAA 20g/Daily vs BCAA 40g/Daily vs BCAA 60g/Daily vs Placebo 20g/Daily · ANOVA · p = 0.945 (To determine if there are significant differences in reported side effects, as measures by MOSES, between the groups.)
PrimaryChange in Monitoring of Side Effects Scale (MOSES)

Change in average score between week 8 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.

Time frame:
8 weeks
Reported as:
Mean · Units on a Scale
Change in Monitoring of Side Effects Scale (MOSES)
Units on a ScaleBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Change in Monitoring of Side Effects Scale (MOSES)-1.3 ± 14.4-4.3 ± 14.4-2.3 ± 9.7-3.2 ± 15.4
Statistical analysis
  • BCAA 20g/Daily vs BCAA 40g/Daily vs BCAA 60g/Daily vs Placebo 20g/Daily · ANOVA · p = 0.861 (To determine if there are significant differences in the change of reported side effects, as measures by MOSES, between the groups.)
PrimaryChange in Monitoring of Side Effects Scale (MOSES)

Change in average score between week 12 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.

Time frame:
12 weeks
Reported as:
Mean · Units on a Scale
Change in Monitoring of Side Effects Scale (MOSES)
Units on a ScaleBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Change in Monitoring of Side Effects Scale (MOSES)2.3 ± 16.8-1.4 ± 13.3-0.4 ± 23.6-2.6 ± 17
Statistical analysis
  • BCAA 20g/Daily vs BCAA 40g/Daily vs BCAA 60g/Daily vs Placebo 20g/Daily · ANOVA · p = 0.747 (To determine if there are significant differences in the change of reported side effects, as measures by MOSES, between the groups.)
PrimaryReasons for Non-adherence

Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Reasons for Non-adherence
ParticipantsBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Side Effects0100
Bad Taste0000
Inconvenience0000
Trouble Remembering0110
No Time0000
Did not feel better0000
Other1010
No reason provided24151728
Multiple Selected1241
PrimaryReasons for Non-adherence

Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Reasons for Non-adherence
ParticipantsBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Side Effects0021
Bad Taste0000
Inconvenience0001
Trouble Remembering0110
No Time0000
Did not feel better0000
Other2111
No reason provided2391116
Multiple Selected1332
PrimaryReasons for Non-adherence

Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Reasons for Non-adherence
ParticipantsBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Side Effects0000
Bad Taste1249
Inconvenience2010
Trouble Remembering0001
No Time0000
Did not feel better2100
Other2002
No reason provided3202
Multiple Selected18181811
PrimaryRecruitment Source

Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)

Time frame:
Year 1
Reported as:
Count of participants · Participants
Recruitment Source
ParticipantsProspective Participant Pool
VA Flyer9
Other4
Research Match3
National Alliance on Mental Illness2
Study Referral6
ClinicalTrials.gov1
Radio11
Sleep Clinic5
PrimaryRecruitment Source

Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)

Time frame:
Year 2
Reported as:
Count of participants · Participants
Recruitment Source
ParticipantsProspective Participant Pool
VA Flyer63
Other7
Research Match28
Study Referral43
ClinicalTrials.gov1
Sleep Clinic1
TROOPS7
PrimaryRecruitment Source

Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)

Time frame:
Year 3
Reported as:
Count of participants · Participants
Recruitment Source
ParticipantsProspective Participant Pool
VA Flyer77
Other10
Research Match9
Study Referral87
Sleep Clinic1
TROOPS26
Lab Website1
Repository18
Newspaper2
NWM Advertisment6
PrimaryRecruitment Source

Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)

Time frame:
Year 4
Reported as:
Count of participants · Participants
Recruitment Source
ParticipantsProspective Participant Pool
VA Flyer52
Other19
Research Match7
Study Referral2
TROOPS14
Repository14
NWM Ad9
PrimaryRecruitment

Number of subjects randomized of those eligible as descriptive percent

Time frame:
Year 1
Reported as:
Count of participants · Participants
Recruitment
ParticipantsEligible Participants
Recruitment13
PrimaryRecruitment

Number of subjects randomized of those eligible as descriptive percent

Time frame:
Year 2
Reported as:
Count of participants · Participants
Recruitment
ParticipantsEligible Participants
Recruitment37
PrimaryRecruitment

Number of subjects randomized of those eligible as descriptive percent

Time frame:
Year 3
Reported as:
Count of participants · Participants
Recruitment
ParticipantsEligible Participants
Recruitment93
PrimaryRecruitment

Number of subjects randomized of those eligible as descriptive percent

Time frame:
Year 4
Reported as:
Count of participants · Participants
Recruitment
ParticipantsEligible Participants
Recruitment16
PrimaryStudy Drug Adherence by Serum

Proportion of study drug consumed assessed by serum of BCAA.

Time frame:
12 weeks

No measurements were reported for this outcome.

PrimaryStudy Drug Adherence by Sleep Diary

Proportion of study drug consumed assessed by sleep diary.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Study Drug Adherence by Sleep Diary
ParticipantsBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
76-100%23131322
51-75%4572
25-50%4655
0-24%33113
Missing61095
PrimaryStudy Drug Adherence by Drug Accounting

Proportion of study drug consumed within each timepoint assessed by drug accounting.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Study Drug Adherence by Drug Accounting
ParticipantsBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
76-100%149918
51-75%6275
25-50%4975
0-24%5383
Missing1114146
PrimaryActiwatch Adherence

Proportion of days with actiwatch worn

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Actiwatch Adherence
ParticipantsBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
76-100%1117
51-75%7366
25-50%117129
0-24%41184
Missing/Not Collected17151811
SecondaryChange in Insomnia Severity Index (ISI) From Baseline

Change in Insomnia Severity Index (ISI) range: 0-28, higher means worse sleep

Time frame:
12 weeks
Reported as:
Mean · Units on a Scale
Change in Insomnia Severity Index (ISI) From Baseline
Units on a ScaleBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Change in Insomnia Severity Index (ISI) From Baseline-2.3 ± 4.3-3.4 ± 6.2-0.9 ± 5.4-1.9 ± 5.3
Statistical analysis
  • BCAA 20g/Daily vs BCAA 40g/Daily vs BCAA 60g/Daily vs Placebo 20g/Daily · ANOVA · p = 0.0947 (To determine if there are significant differences in the Insomnia Severity Index between the groups.)
PrimaryScreen Failures

Number of enrolled participants who were later found ineligible

Time frame:
From enrollment to randomization (~4 weeks)
Reported as:
Count of participants · Participants
Screen Failures
ParticipantsConsented Participants
Screen Failures8
PrimaryIncidence of Non-Participation

Reason for not participating after initial contact and before consent as descriptive percent

Time frame:
From first contact to declining (~1 week)
Reported as:
Count of participants · Participants
Incidence of Non-Participation
ParticipantsIndividuals Who Declined
BCAA Consumption Concerns2
No Reason18
Time Commitment12
Sleep Equipment1
Personal Health Concerns2
PrimaryRetention by Arm

Number of participants retained by study arm

Time frame:
From randomization to study completion (~12 weeks)
Reported as:
Count of participants · Participants
Retention by Arm
ParticipantsBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
Retention by Arm24141824

Adverse events

Collected over from enrollment until end of follow-up, up to 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCAA 20g/Daily0/40 (0%)1/40 (2.5%)14/40 (35%)
BCAA 40g/Daily0/37 (0%)0/37 (0%)8/37 (21.6%)
BCAA 60g/Daily0/45 (0%)1/45 (2.2%)14/45 (31.1%)
Placebo 20g/Daily0/37 (0%)0/37 (0%)10/37 (27%)
Most frequent serious events
Most frequent serious events
EventBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
GallstonesGastrointestinal disorders1/400/370/450/37
Renal FailureRenal and urinary disorders0/400/371/450/37
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/Daily
VomitingGastrointestinal disorders2/403/376/453/37
NauseaGastrointestinal disorders3/402/372/453/37
StomachacheGastrointestinal disorders3/400/372/451/37
Headache/MigraineGeneral disorders2/401/370/450/37
DiarrheaGastrointestinal disorders0/401/372/451/37
Erectile dysfunctionReproductive system and breast disorders0/400/370/451/37
Lung InfectionRespiratory, thoracic and mediastinal disorders0/400/370/451/37
Ear infectionEar and labyrinth disorders0/401/370/450/37
Product QualityProduct Issues1/400/370/450/37
RashGeneral disorders1/400/370/450/37

Baseline characteristics

Represents the number of participants randomized to each arm.

Age, Continuous
Age, Continuous(years)BCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/DailyTotal
Mean47.6 ± 9.448.0 ± 10.150.8 ± 9.550.0 ± 10.049.3 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)BCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/DailyTotal
Female1011111042
Male30263427117
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/DailyTotal
Race/Ethnicity — American Indian/Alaskan00000
Race/Ethnicity — Asian11103
Race/Ethnicity — Black or African American354012
Race/Ethnicity — Native Hawaiian or Other Pacific Islander01001
Race/Ethnicity — Hispanic43119
Race/Ethnicity — White26243530115
Race/Ethnicity — Mixed633416
Race/Ethnicity — Unknown00000
Race/Ethnicity — Other000123
Insomnia Severity Index (ISI)
Insomnia Severity Index (ISI)(Units on a Scale)BCAA 20g/DailyBCAA 40g/DailyBCAA 60g/DailyPlacebo 20g/DailyTotal
Mean14.1 ± 5.814 ± 6.013.3 ± 5.913.2 ± 5.713.6 ± 5.8
08

Study locations

1 site
  • VA Portland Health Care System, Portland, OR
    Portland, Oregon 97207-2964, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — A limited dataset (LDS) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying any individual whose data are included in the dataset.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 6 months after the resulting publication

Access criteria: Final datasets will be maintained locally until institutional resources become available for public access to data sets. Limited de-identified data sets will be made available on a case-by-case basis in response to specific user requests that meet criteria specified above.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2025, 51 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's 51 months is above that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2020
First posted
Oct 26, 2020
StartActual
Jun 1, 2021
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Results first posted
Oct 1, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 1, 2026 · revised Oct 28, 2026
Enrollment
160→175
Oct 28, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 1, 2026
  • EditedStudy Drug Adherence by drug accountingSerumTime frame: Year 1 → 12 weeks
  • EditedStudy drug adherenceDrug Adherence by sleep diarySleep DiaryTime frame: Year 1 → 12 weeks
  • EditedStudy Drug Adherence by serum or sweat assayDrug AccountingTime frame: Year 1 → 12 weeks
  • EditedPatient satisfaction with overall study processSatisfaction With Overall Study ProcessTime frame: 12 weeks
  • EditedReasons for nonNon-adherenceTime frame: 4 weeks
  • EditedChange in Reasons for nonNon-adherenceTime frame: 8 weeks
  • EditedChange in Reasons for nonNon-adherenceTime frame: 12 weeks
  • EditedRecruitment sourceSourceTime frame: Year 1
  • EditedRecruitment sourceSourceTime frame: Year 2
  • EditedRecruitment sourceSourceTime frame: Year 3
  • EditedRecruitment sourceSourceTime frame: Year 4
  • RemovedRetentionTime frame: Year 1
  • RemovedRetention by armTime frame: Year 1
  • RemovedIncidence of non-participationTime frame: Year 1
  • RemovedScreen FailuresTime frame: Year 1
  • RemovedScreen FailuresTime frame: Year 2
  • RemovedScreen FailuresTime frame: Year 3
  • RemovedScreen FailuresTime frame: Year 4
  • RemovedIncidence of non-participationTime frame: Year 2
  • RemovedIncidence of non-participationTime frame: Year 3
  • RemovedIncidence of non-participationTime frame: Year 4
  • RemovedRetention by armTime frame: Year 2
  • RemovedRetention by armTime frame: Year 3
  • RemovedRetention by armTime frame: Year 4
  • RemovedRetentionTime frame: Year 2
  • RemovedRetentionTime frame: Year 3
  • RemovedRetentionTime frame: Year 4
  • RemovedStudy Drug Adherence by serum or sweat assayTime frame: Year 2
  • RemovedStudy drug adherence by serum or sweat assayTime frame: Year 3
  • RemovedStudy drug adherence by serum or sweat assayTime frame: Year 4
  • …and 19 more, on the record history on ClinicalTrials.gov ↗
What changed on Oct 28, 2026
  • AddedScreen FailuresTime frame: From enrollment to randomization (~4 weeks)
  • AddedIncidence of Non-ParticipationTime frame: From first contact to declining (~1 week)
  • AddedRetention by ArmTime frame: From randomization to study completion (~12 weeks)
across 2 updates, Oct 1, 2026 – Oct 28, 2026
Documents
Oct 1, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedChange in Insomnia Severity Index (ISI) From BaselineTime frame: 12 weeks
Oct 1, 2026
Show all 2 updates
  1. Oct 28, 2026
    Posted results revised
    Enrollment 159→175
    Primary outcomes 3 added
    What changed in the outcomes
    • AddedScreen FailuresTime frame: From enrollment to randomization (~4 weeks)
    • AddedIncidence of Non-ParticipationTime frame: From first contact to declining (~1 week)
    • AddedRetention by ArmTime frame: From randomization to study completion (~12 weeks)
    + 1 other change: verification date
  2. Oct 1, 2026
    Results posted
    Documents Study protocol ↗ posted
    Enrollment 160→159
    Primary outcomes 11 edited, 19 removed, 19 more
    What changed in the outcomes
    • EditedStudy Drug Adherence by drug accountingSerumTime frame: Year 1 → 12 weeks
    • EditedStudy drug adherenceDrug Adherence by sleep diarySleep DiaryTime frame: Year 1 → 12 weeks
    • EditedStudy Drug Adherence by serum or sweat assayDrug AccountingTime frame: Year 1 → 12 weeks
    • EditedPatient satisfaction with overall study processSatisfaction With Overall Study ProcessTime frame: 12 weeks
    • EditedReasons for nonNon-adherenceTime frame: 4 weeks
    • EditedChange in Reasons for nonNon-adherenceTime frame: 8 weeks
    • EditedChange in Reasons for nonNon-adherenceTime frame: 12 weeks
    • EditedRecruitment sourceSourceTime frame: Year 1
    • EditedRecruitment sourceSourceTime frame: Year 2
    • EditedRecruitment sourceSourceTime frame: Year 3
    • EditedRecruitment sourceSourceTime frame: Year 4
    • RemovedRetentionTime frame: Year 1
    • RemovedRetention by armTime frame: Year 1
    • RemovedIncidence of non-participationTime frame: Year 1
    • RemovedScreen FailuresTime frame: Year 1
    • RemovedScreen FailuresTime frame: Year 2
    • RemovedScreen FailuresTime frame: Year 3
    • RemovedScreen FailuresTime frame: Year 4
    • RemovedIncidence of non-participationTime frame: Year 2
    • RemovedIncidence of non-participationTime frame: Year 3
    • RemovedIncidence of non-participationTime frame: Year 4
    • RemovedRetention by armTime frame: Year 2
    • RemovedRetention by armTime frame: Year 3
    • RemovedRetention by armTime frame: Year 4
    • RemovedRetentionTime frame: Year 2
    • RemovedRetentionTime frame: Year 3
    • RemovedRetentionTime frame: Year 4
    • RemovedStudy Drug Adherence by serum or sweat assayTime frame: Year 2
    • RemovedStudy drug adherence by serum or sweat assayTime frame: Year 3
    • RemovedStudy drug adherence by serum or sweat assayTime frame: Year 4
    • …and 19 more, on the record history on ClinicalTrials.gov ↗
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedChange in Insomnia Severity Index (ISI) From BaselineTime frame: 12 weeks
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04603443
Responsible party
Sponsor
First posted
Oct 26, 2020
Start date
Jun 1, 2021
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Results posted
Oct 1, 2026
Last update
Oct 28, 2026

Study contacts

Miranda M Lim, MD PhD
principal investigator · VA Portland Health Care System, Portland, OR

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Leucine · Isoleucine · Valine

Start the discussion